Please wait while the formulary information is being retrieved.
TEZSPIRE (tezepelumab-ekko)
- severe persistent asthma
210 mg/1.91 mL (110 mg/mL) subcutaneous syringe
- Inject 210 mg by subcutaneous route every 4 weeks
Default screening record
- Inject 210 mg by subcutaneous route once
- Inject 210 mg by subcutaneous route every 4 weeks
- Inject 1.91 milliliters (210 mg) by subcutaneous route every 4 weeks
- Inject 1.91 milliliters (210 mg) by subcutaneous route once
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- Acute asthma attack
Contraindicated
- Parasitic infection
Severe
Moderate
- None
TEZSPIRE (tezepelumab-ekko)
- severe persistent asthma
- None
- Arthralgia
- Back pain
- Pharyngitis
More Frequent
Severe
Less Severe
- None
- Injection site erythema
- Injection site pain
- Injection site sequelae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hypersensitivity drug reaction
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Tezepelumab-ekko
Safety and effectiveness not established in pediatric patients < 12 years.
- 1 Day – 12 Years
- Safety and effectiveness not established in pediatric patients < 12 years.
Tezepelumab-ekko
- Severity Level:
2
- Additional Notes: Insufficient human data available on developmental toxicity risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Tezepelumab-ekko
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Severe persistent asthma | |
| J45.50 | Severe persistent asthma, uncomplicated |
| 0-9 | A-Z |
|---|---|
| J45.50 | Severe persistent asthma, uncomplicated |
Formulary Reference Tool